Can-Fite will immediately exercise warrants covering up to 1,591,738 ADSs at $2.50 each, seeking approximately $4.0 million in gross proceeds. The cash matters because Can-Fite intends to direct net proceeds toward research and development, clinical trials, Working Capital and general corporate purposes, subject to customary closing conditions.

Key Highlights

  • Can-Fite will exercise warrants covering up to 1,591,738 ADSs at $2.50 per ADS.
  • The transaction includes new unregistered warrants for up to 3,183,476 ADSs, also priced at $2.50 per ADS.
  • H.C. Wainwright & Co. is serving as exclusive Placement agent, with closing expected on or about September 3.

Can-Fite BioPharma Ltd. (AMEX: CANF) expects approximately $4.0 million in gross cash proceeds from an immediate Warrant exercise, before placement fees and offering expenses. The transaction is subject to customary closing conditions and is expected to close on or about September 3, with net proceeds intended for research, Clinical Trials and corporate needs.

Warrant Terms and Registration Plans

The agreement covers outstanding warrants issued in March 2026, originally carrying a $5.00 exercise price per ADS. Can-Fite will reduce that price to $2.50 for the immediate cash exercise of warrants covering up to 1,591,738 ADSs. In return, Can-Fite will issue new unregistered warrants covering up to 3,183,476 ADSs, with an exercise price of $2.50 per ADS.

Research and Clinical Funding

The new warrants were offered through a private placement relying on an exemption from registration requirements under the 1933 Act.

Peers Moving on This News